. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

糖心原创

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

糖心原创

Skip to main content
ioGlutamatergic Neurons MAPT S305N;P301S/S305N;P301S
糖心原创-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-4r-tau-expression
bitbio-ioGlutamatergic-Neurons-media-kits
糖心原创-io1115-glutamatergic-neurons-mapt-s305n-hom-gene-expression-3r-4r-isoforms-2
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-4r-tau
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-phospho-tau
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-protein-expression-4r-tau-2
糖心原创-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining
mRNA transfection of human iPSC-derived neurons with GFP.
bitbio-lipid-delivery-glutamatergic-neurons-GFP-quantification
糖心原创-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-4r-tau-expression
bitbio-ioGlutamatergic-Neurons-media-kits
糖心原创-io1115-glutamatergic-neurons-mapt-s305n-hom-gene-expression-3r-4r-isoforms-2
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-4r-tau
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-phospho-tau
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-protein-expression-4r-tau-2
糖心原创-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining
mRNA transfection of human iPSC-derived neurons with GFP.
bitbio-lipid-delivery-glutamatergic-neurons-GFP-quantification

cat no | io1117

ioGlutamatergic Neurons MAPT S305N;P301S/S305N;P301S

Human iPSC-derived neuronal 4R tau model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • Functional excitatory neurons engineered with a double homozygous S305N and P301S mutation in MAPT for FTD, Alzheimer's disease and tauopathy research

  • Equimolar ratio of 4R:3R MAPT demonstrated by RT-qPCR and Western blotting

Place your order

糖心原创-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-4r-tau-expression

Human iPSC-derived neuronal 4R tau model

Expression of 4R tau in ioGlutamatergic Neurons carrying a double homozygous S305N and P301S mutation in the MAPT gene.
bitbio-ioGlutamatergic-Neurons-media-kits

ioGlutamatergic Neurons Media Kit

Cell culture media kit for the culture of ioGlutamatergic Neurons up to 14 days post-thaw

Learn more about the product >

糖心原创-io1115-glutamatergic-neurons-mapt-s305n-hom-gene-expression-3r-4r-isoforms-2

Adult-like 4R:3R tau isoform expression

MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.

RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: ; 3R MAPT: , 4R MAPT: ). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.

糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-4r-tau

Western blot confirms the presence of 4R tau protein in MAPT S305N disease model cells

Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons

Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.

Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay kit.  Lysates were pre-treated with lambda phosphatase (3h at 30掳C).

Cell lysates and a tau ladder positive control were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 90 min) and transferred to a PVDF membrane; 5 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Anti-Tau antibody [TAU-5] (, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-phospho-tau

MAPT S305N disease model cells show tau hyperphosphorylation

The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.

Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).

Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 75 min) and transferred to a PVDF membrane; 10 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (, 1:1000), Anti-Tau (phospho S396) antibody [E178] (, 1:1000), Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).

糖心原创-glutamatergic-neurons-mapt-s305n-p301s-protein-expression-4r-tau-2

4R tau is absent in the wild-type and most abundant in the MAPT S305N/S305N disease model cells

Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.

Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (). Fluorescent signals were visualised using an ImageXpress microscope.

糖心原创-triculture-glutamatergic-neurons-astrocytes2-microglia-immunofluorescent-staining

Advanced tri-culture of ioGlutamatergic Neurons, ioAstrocytes 2.0, and ioMicroglia

While neuronal-astrocyte co-cultures capture essential structural and metabolic synergy, the addition of microglia, the resident myeloid cells of the CNS, is critical for accurately modelling neuroinflammatory pathways, synaptic pruning, and homeostatic maintenance.

This representative immunocytochemistry image demonstrates a successful tri-culture established at a 2:1:2 ratio (neurons:astrocytes:microglia). Using an optimised 糖心原创 protocol for 24-well plates, the tri-culture can be robustly maintained for up to 7 days. Staining with cell type-specific markers confirms the presence and integration of all three populations, shown alongside single-channel panels: MAP2-positive ioGlutamatergic Neurons (red), S100B-positive ioAstrocytes 2.0 (cyan), and IBA1-positive ioMicroglia (yellow); with DAPI as a nuclear counterstain (blue). Scale bars: 200 碌m.

mRNA transfection of human iPSC-derived neurons with GFP.

Efficient mRNA transfection into ioGlutamatergic Neurons

ioGlutamatergic Neurons are efficiently transfected and show sustained long-term expression of mRNA encoding GFP. ioGlutamatergic Neurons were imaged from day 1 post-thaw and throughout the experiment to assess transfection efficiency and evaluate potential cytotoxic effects of the transfection protocol. Day 1 images were captured prior to transfection on the same day.

Download the step-by-step protocol for lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons.

bitbio-lipid-delivery-glutamatergic-neurons-GFP-quantification

Lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons

ioGlutamatergic Neurons were transfected 24 hours post-thaw using Lipofectamine鈩� Stem Transfection Reagent. The transfection efficiency was evaluated by fluorescence imaging over 18 days after mRNA delivery, resulting in high transfection efficiency (close to 100%) and long-term sustained GFP expression.

Quantification of the GFP signal shows a decrease in GFP intensity over time, while the percentage of GFP-positive cells remains largely unchanged over time.

(A) The percentage of GFP-positive cells from two independent experiments.

(B) GFP intensity, quantified in successfully transfected cells from two independent experiments is quantified and normalised to day 2 (24 hours post-transfection).

Explore the full dataset and complete protocol for lipid-based delivery of synthetic mRNA in 96-well plates

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@糖心原创.

Human iPSC-derived neuronal model expressing 4R tau

A rapidly maturing, physiologically relevant, functional system for tauopathy, frontotemporal dementia (FTD) and Alzheimer's disease (AD) research.

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] are opti鈥憃x deterministically programmed excitatory neurons engineered with a double homozygous S305N and P301S mutation in the MAPT gene.

While adult human brains express an equimolar ratio of 3R and 4R tau isoforms, traditional iPSC-derived neurons typically express very low levels of 4R tau, even in long-term culture. In this model, the homozygous S305N mutation accelerates exon 10 inclusion, driving an adult-like equimolar 4R:3R tau ratio by day 11 of culture, confirmed by RT-qPCR and Western blotting.

Additional disease model cells are available that carry the homozygous S305N mutation alone, or a homozygous S305N and heterozygous P301S mutation in the MAPT gene.

This model is genetically matched to our wild-type ioGlutamatergic Neurons, which serve as a robust control for translational research and high-throughput drug screening. It complements our broader Alzheimer's disease portfolio, which includes ioGlutamatergic Neurons carrying MAPT S305N, APP V717I, APP KM670/671NL, or PSEN1 M146L mutations, alongside disease-relevant mutations in ioGABAergic Neurons and ioMicroglia.

Benchtop benefits

Expression of 4R tau

Accelerated tauopathy model

Equimolar 4R:3R tau confirmed by RT-qPCR and Western blotting.

Compare disease model with wild type control

Make true comparisons

Pair with wild-type glutamatergic neurons to investigate the impact of the S305N and P301S double mutation.

Glutamatergic neurons are quick to culture

Quick

Cells are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 10鈦� viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm虏

User storage

LN2 or -150掳C

Format

Cryopreserved cells

Genetic modification

Double homozygous S305N and P301S mutation in the MAPT gene

Applications

FTD, AD and tauopathy research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

 

Scale your study with volume pricing

Enabling scientists to use human cells in their research, running additional experiments without rationing cells or limiting experimental scale

 

Order quantity Total vials received Pricing tier 
1 - 9 packs 3 - 27 vials Standard price
10 - 33 packs 30 - 99 vials Automatic 10% discount
> 34 packs > 100 vials > Contact us for a quote

 

Academic pricing: Academic users can purchase any ioCells in 3-vial packs ($/鈧�/拢 999 per pack), available year-round with any cell type combination.
Technical data

Adult-like 4R:3R tau isoform expression

Cells carrying the S305N mutation express equimolar 4R:3R MAPT isoforms by day 11

糖心原创-io1115-glutamatergic-neurons-mapt-s305n-hom-gene-expression-3r-4r-isoforms-2

MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.

RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: ; 3R MAPT: , 4R MAPT: ). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

Western blot confirms the presence of 4R tau protein in MAPT S305N disease model cells

糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-4r-tau

Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons

Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.

Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay Kit.  Lysates were pre-treated with lambda phosphatase (3h at 30掳C).

Cell lysates and a tau ladder positive control were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 90 min) and transferred to a PVDF membrane; 5 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Anti-Tau antibody [TAU-5] (, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

MAPT S305N disease model cells show tau hyperphosphorylation
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-phospho-tau

The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.

Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).

Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 75 min) and transferred to a PVDF membrane; 10 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (, 1:1000), Anti-Tau (phospho S396) antibody [E178] (, 1:1000), Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

4R tau is absent in the wild-type and most abundant in the MAPT S305N/S305N disease model cells

糖心原创-glutamatergic-neurons-mapt-s305n-p301s-protein-expression-4r-tau-2

Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.

Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (). Fluorescent signals were visualised using an ImageXpress microscope.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N hom (io1115)
ioGlutamatergic Neurons MAPT S305N hom P301S het (io1116)

Highly characterised and defined

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] express neuron-specific markers comparably to the wild type control

bitbio-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-protein-expression-map2-tubb3

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] compared to the genetically matched control; (10x objective).

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] form structural neuronal networks by day 11

bitbio-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-morphology

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; (10x objective).

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic cell programming

糖心原创-io1117-glutamatergic-neurons-mapt-s305n-p301s-hom-gene-expression-rt-qpcr

Gene expression analysis demonstrates that ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] and wild type ioGlutamatergic Neurons (WT Control) lack the expression of the pluripotency marker POU5F1 (OCT4) at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

View the step-by-step RNA extraction and RT-qPCR protocol used to generate this data 

Industry leading seeding density

糖心原创 Glutamatergic neurons APP V717I hom are suitable for culture in 96-well and 384-well plates for screening applications

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Technical data

Adult-like 4R:3R tau isoform expression

Cells carrying the S305N mutation express equimolar 4R:3R MAPT isoforms by day 11
糖心原创-io1115-glutamatergic-neurons-mapt-s305n-hom-gene-expression-3r-4r-isoforms-2

MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.

RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: ; 3R MAPT: , 4R MAPT: ). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

Western blot confirms the presence of 4R tau protein in MAPT S305N disease model cells
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-4r-tau

Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons

Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.

Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay Kit.  Lysates were pre-treated with lambda phosphatase (3h at 30掳C).

Cell lysates and a tau ladder positive control were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 90 min) and transferred to a PVDF membrane; 5 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Anti-Tau antibody [TAU-5] (, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

MAPT S305N disease model cells show tau hyperphosphorylation
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-western-blot-phospho-tau

The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.

Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).

Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4鈥�20% Mini-PROTEAN庐 TGX Stain-Free鈩� gel (120V, 75 min) and transferred to a PVDF membrane; 10 渭g protein was loaded.

Membranes were blocked (10 min) and incubated overnight at 4掳C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (, 1:1000), Anti-Tau (phospho S396) antibody [E178] (, 1:1000), Anti-GAPDH antibody [6C5] (, 1:5000). Signal was detected via ECL following secondary antibody incubation.

Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)

4R tau is absent in the wild-type and most abundant in the MAPT S305N/S305N disease model cells
糖心原创-glutamatergic-neurons-mapt-s305n-p301s-protein-expression-4r-tau-2

Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.

Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (). Fluorescent signals were visualised using an ImageXpress microscope.

View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N hom (io1115)
ioGlutamatergic Neurons MAPT S305N hom P301S het (io1116)

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

How to prepare tissue culture vessels with PDL-Geltrex for culture

Dr Kaiser Karim will take you through the step-by-step process of coating your culture plate with PDL-Geltrex before the revival of ioGlutamatergic Neurons.

Since recording this video Geltrex has been replaced by Geltrex Flex; refer to the user manual for full details. 

Frequently Asked Questions (FAQs)

Why are the S305N and P301S mutations in the MAPT gene relevant for disease modelling?

The MAPT gene encodes tau, a microtubule-associated protein central to Alzheimer鈥檚 disease (AD) pathology. However, most pathogenic MAPT variants, including the S305N and P301S mutations, are associated with frontotemporal dementia (FTD). The S305N mutation, located in exon 10, destabilises a stem-loop structure, increasing both 4R tau expression and tau hyperphosphorylation.

The P301S mutation, also located in exon 10, similarly drives tau hyperphosphorylation. In patients, it enhances aggregation and seeding potency, and induces widespread transcriptomic and proteomic alterations. Consequently, ioGlutamatergic Neurons carrying a double homozygous S305N and P301S mutation in the MAPT gene serve as a human-relevant in vitro model for investigating the molecular and cellular mechanisms underlying FTD, AD and tauopathies.

 

What disease models are available from 糖心原创 to study the effects of mutations in the MAPT gene?

糖心原创 offers ioGlutamatergic Neurons carrying a homozygous S305N MAPT mutation, either alone or paired with a heterozygous or homozygous P301S mutation. These three products enable scientists to study the synergistic impact of mutations in the MAPT gene alongside their genetically matched, wild-type control.

 

Is there a genetically matched wild-type control available for the MAPT S305N;P301S iPSC-derived neuronal model?

糖心原创 offers the ioGlutamatergic Neurons carrying the double homozygous MAPT S305N and P301S mutation alongside a genetically matched wild-type control. Together, these ioGlutamatergic Neurons provide a physiologically relevant model to study how the S305N and P301S mutations drive FTD mechanisms and tau hyperphosphorylation in excitatory neurons.

 

Do the MAPT S305N;P301S ioGlutamatergic Neurons display phenotypic differences compared to the wild-type control?

The homozygous MAPT S305N mutation in ioGlutamatergic Neurons accelerates exon 10 inclusion, driving an adult-like, equimolar 4R:3R tau ratio by day 11 of culture, confirmed by RT-qPCR and Western blotting.

 

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

糖心原创_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664